Page last updated: 2024-08-24

irinotecan and Nervous System Diseases

irinotecan has been researched along with Nervous System Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Cid, NG; Labandeira, CM; Manrique, MCA; Mata, JG; Montes, AF; Núñez, MÁ; Ron, DA; Vera, R	1
Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ	1
Gotwald, T; Hutterer, M; Jacobs, AH; Kostron, H; Muigg, A; Nowosielski, M; Putzer, D; Staffen, W; Stockhammer, G; Tinkhauser, G; Trinka, E; Virgolini, IJ; Waitz, D	1

Reviews

1 review(s) available for irinotecan and Nervous System Diseases

Article	Year
Maintenance treatment in metastatic colorectal cancer: in search of the best strategy. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment	2020

Article

Year

Maintenance treatment in metastatic colorectal cancer: in search of the best strategy.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:8

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Disease Progression; Erlotinib Hydrochloride; Fluorouracil; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Maintenance Chemotherapy; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Panitumumab; Withholding Treatment

2020

Trials

1 trial(s) available for irinotecan and Nervous System Diseases

Article	Year
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas, 2016, Volume: 45, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting	2016

Article

Year

A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.

Pancreas, 2016, Volume: 45, Issue:3

Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Hedgehog Proteins; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Nervous System Diseases; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome; Veratrum Alkaloids; Vomiting

2016

Other Studies

1 other study(ies) available for irinotecan and Nervous System Diseases

Article	Year
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:6 Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Image Processing, Computer-Assisted; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron-Emission Tomography; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Failure; Tyrosine; Ultrasonography	2011

Article

Year

O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2011, Volume: 52, Issue:6

Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Image Processing, Computer-Assisted; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron-Emission Tomography; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Failure; Tyrosine; Ultrasonography

2011